# AstraZeneca Plc and Daiichi Sankyo enter collaboration in novel

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-and-daiichi-sankyo-enter-collaboration-in-novel/412770874
- Published: 2019-03-29T07:26:28+00:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has entered into a global development and commercialisation collaboration agreement
with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan(
DS-8201), a proprietary antibody-drug conjugate (ADC) and potential new targeted
medicine for cancer treatment.

The collaboration is aligned with AstraZeneca’s science-led strategy in Oncology,
which is based on four key scientific platforms: tumour drivers & resistance, DNA
damage response, Immuno-Oncology and ADCs.

Trastuzumab deruxtecan is currently in development for the treatment of multiple
HER2-expressing cancers, including breast and gastric cancer, and in patients with
HER2-low expression. In 2017, trastuzumab deruxtecan was granted Breakthrough Therapy
Designation by the US FDA for the treatment of patients with HER2-positive, locally-
advanced or metastatic breast cancer who have been treated with trastuzumab and 
pertuzumab and have disease progression after trastuzumab emtansine.

A first regulatory submission is scheduled for the second half of 2019 for patients
in the advanced or refractory breast cancer setting. Additional development for 
the treatment of breast, non-small cell lung cancer (NSCLC), gastric and colorectal
cancers is ongoing.

The companies will jointly develop and commercialise trastuzumab deruxtecan worldwide,
except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo
will be solely responsible for manufacturing and supply.

> **Pascal Soriot, Chief Executive Officer, said:** “We believe that trastuzumab
> deruxtecan could become a transformative new medicine for the treatment of HER2-
> positive breast and gastric cancers. In addition, it has the potential to redefine
> breast cancer treatment as the first therapy for HER2-low expressing tumours. 
> It also has the potential to treat other HER2-mutated or HER2-overexpressing cancers,
> including lung and colorectal cancers. We are proud to be working with Daiichi
> Sankyo, a long-term collaborator of AstraZeneca in other disease areas.”
> George Nakayama, Representative Director, Chairman and Chief Executive Officer
> of Daiichi Sankyo, said: “Trastuzumab deruxtecan is the flagship asset in our 
> oncology pipeline created by our relentless pursuit of science and technology,
> the most important strengths of our company. Through the strategic collaboration
> with AstraZeneca, a company with a wealth of global experience and expertise in
> oncology, we will combine our respective skill sets to maximise the value of trastuzumab
> deruxtecan and accelerate the establishment of our global oncology business. By
> aiming to provide new treatment options across a wide range of cancers as soon
> as possible, we will maximise our contribution to patients with cancer and their
> families around the world.”

Using Daiichi Sankyo’s DXd proprietary ADC technology, trastuzumab deruxtecan has
been designed to deliver chemotherapy selectively to cancer cells and reduce systemic
exposure, in contrast to conventional chemotherapy delivery. Data from the ongoing
first-time-in-human trial shows strong activity in a number of tumour types. In 
particular, the strength of the overall response rate and durability of response
in patients previously treated with trastuzumab emtansine for HER2-positive metastatic
breast cancer formed the basis for the Breakthrough Therapy Designation.1

**Financial considerations**

Under the terms of the agreement, AstraZeneca will pay Daiichi Sankyo an upfront
payment of $1.35bn, half of which is due upon execution, with the remainder payable
12 months later.

Contingent payments of up to $5.55bn include $3.8bn for potential successful achievement
of future regulatory and other milestones, as well as $1.75bn for sales-related 
milestones.

Overall, the transaction will be accounted for as an intangible asset acquisition,
recognised initially at the present value of non-contingent consideration, with 
future milestones capitalised into the intangible asset as they are recognised. 
AstraZeneca and Daiichi Sankyo will share equally development and commercialisation
costs as well as profits from trastuzumab deruxtecan worldwide, except for Japan.

Daiichi Sankyo will record sales in the US, certain countries in Europe and certain
other markets where Daiichi Sankyo has affiliates. Further to the financial reporting
announcement below, profits shared with AstraZeneca will be accounted for as Collaboration
Revenue by AstraZeneca (see further below, ‘Financial reporting presentation’).

AstraZeneca is expected to record Product Sales in all other markets worldwide for
which profits shared with Daiichi Sankyo will be accounted for as cost of goods 
sold.

The transaction is expected to be neutral to core earnings in 2019, with growing
Core EPS accretion from 2020 and making a significant contribution in 2023. There
are no closing conditions to the transaction. The collaboration agreement will become
effective on 29 March 2019. The transaction and funding arrangements do not impact
the Company’s financial guidance for 2019 as published on 14 February 2019.

The upfront payment and near-term milestones under the transaction will be funded
from the proceeds of a new equity placement of approximately $3.5bn, of which more
than half will be used to fund this transaction and the ongoing collaboration. A
separate announcement will be issued by the Company today on the equity placement.

For the purposes of the UK Listing Authority’s Listing Rule LR 10.4.1 R (Notification
of class 2 transactions), the value of gross assets acquired with the transaction
is estimated to be $1.5bn and, in view of the development phase of the medicine,
a pre-tax loss of $38m was attributable to trastuzumab deruxtecan during the year
to 31 March 2018.

**About Trastuzumab deruxtecan**

Trastuzumab deruxtecan (DS-8201; [fam-] trastuzumab deruxtecan in US only) is the
lead potential new medicine in the ADC franchise of the Daiichi Sankyo Cancer Enterprise.
ADCs are targeted cancer medicines that deliver cytotoxic agents to cancer cells
via a linker attached to a monoclonal antibody that binds to a specific target expressed
on cancer cells.

A broad and comprehensive development programme with trastuzumab deruxtecan is underway
in North America, Europe and Asia, including five pivotal trials in HER2-expressing
breast and gastric cancers. Trastuzumab deruxtecan is also in Phase II development
for HER2-expressing advanced colorectal cancer and metastatic non-squamous HER2-
overexpressing or HER2-mutated NSCLC, and Phase I development in combination with
nivolumab for HER2-expressing metastatic breast and bladder cancers.

Trastuzumab deruxtecan was granted Breakthrough Therapy Designation in 2017 by the
US FDA for the treatment of patients with HER2-positive, locally-advanced or metastatic
breast cancer who have been treated with trastuzumab and pertuzumab and have disease
progression after trastuzumab emtansine. Fast Track Designation was also granted
in the US for the treatment of HER2-positive unresectable and/or metastatic breast
cancer in patients who have progressed after prior treatment with HER2-targeted 
medicines, including trastuzumab emtansine. Trastuzumab deruxtecan has received 
Sakigake designation for the treatment of HER2-positive advanced gastric or gastroesophageal
junction cancer by the Japan Ministry of Health, Labour and Welfare.

Trastuzumab deruxtecan is a potential new medicine that has not been approved for
any indication in any country. Safety and efficacy have not been established.

**Financial reporting presentation**

As a result of this announcement, AstraZeneca also updates the presentation of Total
Revenue within its Statement of Comprehensive Income. This is effective from 1 January
2019 and will be reflected in the Company’s Q1 2019 financial results that are intended
for publication on 26 April 2019.

In 2015, the Company announced a change to the presentation of Total Revenue within
its Statement of Comprehensive Income to include Externalisation Revenue. Today’s
announcement recognises the growing importance of collaborations to AstraZeneca 
and will result in income arising from those collaborations being recognised within
Total Revenues. The associated costs of collaborations will be recognised in the
appropriate expense lines in the Statement of Comprehensive Income.

Historically, Externalisation Revenue only included income arising from transactions
involving AstraZeneca’s medicines. Such income included upfronts, milestones receipts
and royalties, as well as other income from collaborations. The updated category
of Collaboration Revenue will also include income of a similar nature arising from
transactions where AstraZeneca has acquired an interest in a medicine and entered
into an active collaboration with the seller.

No prior year restatement of financial results will be required as a result of this
change. The change in accounting presentation does not impact the Company’s revenue
guidance for 2019.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on:
